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Associations between Use of Antimalarial Medications and Health among U.S. Veterans of the
Wars in Iraq and Afghanistan
Aaron I. Schneiderman,1* Yasmin S. Cypel,1 Erin K. Dursa,1 and Robert M. Bossarte2
1Department of Veterans Affairs, Epidemiology Program, Post Deployment Health Services (10P4Q), Office of Patient Care Services, Veterans
Health Administration, Washington, District of Columbia; 2Department of Behavioral Medicine and Psychiatry, West Virginia University Injury
Control Research Center, West Virginia University School of Medicine, Morgantown, West Virginia
Abstract. Mefloquine (Lariam®;RocheHoldingAG,Basel, Switzerland) hasbeen linked to acuteneuropsychiatric side
effects. This is a concern for U.S. veterans who may have used mefloquine during recent Southwest Asia deployments.
Using data from the National Health Study for a New Generation of U.S. Veterans, a population-based study of U.S.
veterans who served between 2001 and 2008, we investigated associations between self-reported use of antimalarial
medications and overall physical and mental health (MH) using the twelve-item short form, and with other MH outcomes
using the post-traumatic stress disorder Checklist-17 and the Patient Health Questionnaire (anxiety, major depression,
and self-harm). Multivariable logistic regression was performed to examine associations between health measures and
seven antimalarial drug categories: any antimalarial, mefloquine, chloroquine, doxycycline, primaquine, mefloquine plus
any other antimalarial, and any other antimalarial or antimalarial combinationwhile adjusting for the effects of deployment
and combat exposure. Data from 19,487 veterans showed that although antimalarial use was generally associated with
higher odds of negative health outcomes, once deployment and combat exposure were added to the multivariable
models, the associations with each of the MH outcomes became attenuated. A positive trend was observed between
combat exposure intensity and prevalence of the five MH outcomes. No significant associations were found between
mefloquine and MH measures. These data suggest that the poor physical and MH outcomes reported in this study
population are largely because of combat deployment exposure.
INTRODUCTION
The relationship between antimalarial medications used
for chemoprophylaxis and a range of adverse outcomes is
documented by case reports and survey studies; however,
findings and estimates of risk associated with malaria che-
moprophylaxis have been inconsistent and frequently poorly
defined.1,2 The adverse outcomes reported and investigated
are most notably dermatological, gastrointestinal (GI), and
neuropsychiatric (e.g., includes both central and peripheral
nervous system disorders such as headache and dizziness,
and psychiatric disorders such as anxiety and depression).3–5
The importance and impact of the possible side effects of
antimalarial medication is especially significant for more than
2.7 million U.S. military service members and veterans who
served in Southwest Asia and other countries with endemic
malaria.6–8 During this time, recognition of the potential side
effects profiles for some medications, specifically mefloquine
(Lariam®;RocheHoldingAG,Basel, Switzerland), has resulted
in changes to U.S. Department of Defense (DoD) policy and
prescribing practices.9,10
Antimalarial drugprofiles,military operational requirements,
and the regional presence of drug-resistantmalaria strains are
all factors that guide policy and practice regarding the use of
specific chemoprophylactic agents.6,11,12 The medications
that satisfy policy and prevention requirements may have
known side effects that influence prescribing practices and
adherence. Doxycycline is well tolerated when used for pro-
phylaxis, but GI complaints and photosensitivity are common
side effects,13–16 and an increased risk for development of
irritable bowel syndrome and inflammatory bowel disease has
also been suggested17; GI tolerability is usually improved with
administration of enteric-coated forms of doxycycline hyclate,
a main form of doxycycline,18 or with use of its monohydrate
derivative.13 For chloroquine, the most serious side effects
noted include retinopathy,4,19–22 cardiomyopathy,4,22 myop-
athy,22 and neuromyopathy.4,22 Primaquine has a long history
of use and is effective against the various life stages of the
Plasmodium species, the malarial parasites, but carries the
significant danger of hemolysis in glucose-6-phosphate
dehydrogenase–deficient populations.23 Besides its effect
on red blood cell metabolism, another adverse consequence
of primaquine use is GI upset.24
Mefloquine use has been linked to reports of acute neuro-
psychiatric side effects in both civilian and military
populations,25–32 particularly in those with a history of psy-
chiatric disorders.29,33,34 The package insert for mefloquine
advises against prescribing it to individuals with a psychiatric
disorder or a history of seizures because of product safety
concerns based on case reports and clinical studies. This has
led to the addition by the manufacturer of a U.S. Food and
Drug Administration black-box package warning in 2013 that
addresses acute neuropsychiatric effects and the possibility
of persistent or permanent neurologic health outcomes.35
Concerns over acute and potential long-term effects from the
use of mefloquine in military personnel have resulted in DoD
policy changes prioritizing the selection of other chemopro-
phylactic agents in place of mefloquine during recent military
conflicts.6,11,12 Mefloquine’s neuropsychiatric effects may
occur through the inhibition of neurotransmitters such as
acetylcholinesterase.36
Overall, the burden of mental health (MH) disorders among
veterans of the U.S. military engagements in Afghanistan
(Operation Enduring Freedom [OEF]) and Iraq (Operation Iraqi
Freedom [OIF]) has been a significant concern for Veterans
Affair and DoD and a significant driver of health-care
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utilization.37–39 Both epidemiological research and health-
care utilization figures demonstrate the high level of MH di-
agnoses and symptoms among these military personnel and
veterans that stem from deployment-related exposures. The
potential for neuropsychiatric effects from the administration
ofmefloquinemay be related to a concomitant increase inMH
concerns, including post-traumatic stress disorder (PTSD),
anxiety disorders, depression, and suicide.40
This study examines whether the use of mefloquine and
other antimalarial medications in a population of OEF/OIF
veterans is associated with self-reported MH conditions and
measures of functional health status, while considering the
independent effects of deployment and combat exposure.
MATERIALS AND METHODS
Study population. The Department of Veterans Affairs (VA)
2009–2011NationalHealthStudy for aNewGenerationofU.S.
Veterans (“NewGen”) study sampled 30,000 OEF/OIF vet-
erans (deployed) and 30,000 non-OEF/OIF veterans who
served in the military between October 2001 and June 2008
(nondeployed), including veterans in the reserves or National
Guard who had not separated from these military compo-
nents. The sample (N = 60,000) was selected from a sample
frame generated from data files provided by the DoD Defense
Manpower Data Center and the VA/DoD Identification Re-
pository database and was stratified by branch of service (Air
Force, Army,Marines, andNavy), unit component (activeduty,
reserve, or National Guard), and gender. A 20% oversample
for women was included to achieve adequate panel repre-
sentation.41 Survey data were collected between 2009 and
2011 using tailored design methodology for mail, telephone,
and web-based modes.42 The response rate was 34.3% (N =
20,563).41 The study was approved by theWashington DC VA
Medical Center Institutional Review Board.
Antimalarial use. Respondents were asked whether they
ever took medications to prevent malaria during their military
service and if “yes,”marked the type of antimalarial taken based
on the following response options: mefloquine, chloroquine
(Aralen®; Sanofi Aventis, Bridgewater, NJ), doxycycline
(Vibramycin®; Pfizer, Inc., NewYork,NY), primaquine, or “other.”
When possible, “other” responses were recoded into existing
options. All responses were then classified depending on
whether use of a single drug was reported or if multiple antima-
larials were used. The resultant antimalarial classification used
for analyses consisted of mefloquine, chloroquine, doxycycline,
primaquine,mefloquineusedwithotherantimalarials (ahistoryof
using two or three different drugs), and other antimalarials
(a single antimalarial and a history of two or three different drugs,
excluding mefloquine combinations), and drug type not speci-
fied.For any reportsofmultipleantimalarials (sometimes referred
to as “combinations”), no data on whether they were adminis-
tered together or at different times were collected. Except for
reports of four or more antimalarials used, all combinations of
mefloquine usewere examined (reports of mefloquine and other
antimalarials) because of its possible association with neuro-
psychiatric symptoms.25–32,40,43–46 Antimalarial drug status was
basedon the surveyquestionsdescribedpreviously anddefined
on three levels: whether an antimalarial drug was taken but not
specified (“unknown” type), one or more specific drugs were
taken (“known” type), or no drugs were taken. Antimalarial drug
use was specified as either used or not used.
Combat exposure. An individual’s exposure to military
combat was assessed based on a dichotomous response
(yes/no) to three survey questions adapted from the DoD Post
DeploymentHealthAssessment form (DD2796): “Didyouever
feel that youwere ingreat danger of being killed?” “Did yousee
anyone wounded, killed, or dead?” “Were you engaged in
direct combat where you discharged your weapon?”47 Sum-
mary scores were created that ranged from 0 to 3 where in-
creasing scores represented increasing combat exposure
intensity. The internal consistency of these items was
assessed using Cronbach’s alpha.48
Health outcome measures and indices. Mental and
physical health outcomes were based on responses to items
included in the NewGen questionnaire. Mental and physical
health component scores were determined using the Medical
Outcomes Study twelve-item short form (SF-12)49 to assess
overall mental and physical health that can be compared with
nationalU.S. normshaving amean (± standarddeviation) of 50
(±10). A positive outcome for PTSDwas determined based on
scores from the 17-item PTSD checklist (PCL-C).50 A PCL
cutoff of 50 or higher was used to identify those screening
positive for PTSD.37,51 Scales from the self-administered
version of the Patient Health Questionnaire (PHQ),52 were
scored for major depression, thoughts of death or self-harm,
and other anxiety disorders. Six health indices were examined
in total (SF-12 Composite Mental Health Score, SF-12 Com-
posite Physical Health Score, PTSD, thoughts of death/self-
harm, other anxiety disorders, and major depression).
Deployment status and other individual characteristics.
Sociodemographic and military service characteristics were
included in statistical models. Self-reported deployment to
OEF/OIF (deployed/not deployed) and sample frame data for
branch of service (Army, Air Force, Marine Corps, and Navy)
and service component (active duty, reserve, National Guard)
were examined. The sociodemographic characteristics were
gender, age group (24–34, 35–44, 45–54, and ³ 55), education
(high school/General Equivalency Diploma, some college/asso-
ciate’s degree, bachelor’s degree, or higher), race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic, Asian, American
Indian or Alaska native, native Hawaiian/Pacific Islander, other),
current household income (<$35,000, $35,000–49,999, $50,000–
74,999, $75,000–99,999, $100,000–149,999, and ³ $150,000),
current employment status (yes/no), and marital status (mar-
ried, separated/divorced, widowed, and never married/single).
All the sociodemographic data, except for age, were based on
self-reports; age data were obtained from the sample frame.
Statistical analyses. SAS® software version 9.4 (SAS In-
stitute, Inc., Cary, NC) was used to generate all statistical
output.53Cross-tabulations for eachof the sociodemographic
and military service characteristics with antimalarial drug
statuswere completed todescribe sample characteristics and
preliminary associations among deployment status, antima-
larial use, andhealth outcomes.χ2 statisticsweregenerated to
check for statistical significance of these associations.Means
and their standard errors were computed for the SF-12 com-
posite mental and physical health scores by deployment
status and within deployment status by all categories of an-
timalarial drug use. Dichotomous outcome variables were
created; individuals’ SF-12 composite scores were coded as
either 1 (above U.S. mean) or 0 (below mean).
Multivariable logistic regression was used to examine as-
sociations between each of the six health indices (dependent
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variables) and seven antimalarial drug categories (any anti-
malarial, mefloquine, chloroquine, doxycycline, primaquine,
mefloquine plus any other antimalarial, and any other anti-
malarial or combination of antimalarials; “type not specified”
was excluded) while controlling for sociodemographic and
military service characteristics. Three models were examined
to better understand the independent effects of deployment
and combat exposure on the association between health
outcome and antimalarial drug use. Model 1 (“demographic”)
examined the relationship between health outcome and anti-
malarial drug use while controlling for gender, age group,
education, race/ethnicity, income, employment status,marital
status, component, and branch of service. Model 2 (“de-
ployment”) examined the relationship between health out-
come and antimalarial drug use but added deployment as an
independent variable and a first-order interaction term
(deployment × antimalarial). Model 3 (“combat exposure”)
paralleled model 2 except that combat exposure was added.
Interaction terms were tested for significance and dropped
from models if found not to be statistically significant; if as-
sociations between health outcome and antimalarial drug
differed significantly when stratified by deployment status,
they were reported separately. Adjusted odds ratios (AORs)
and 95% confidence intervals (CIs) are reported for each of
the three models by outcome and antimalarial drug. Each of
these three regressions modeled the odds of having SF-12
composite scores fall below the U.S. mean versus the odds
of having scores above the U.S. mean. When PTSD, suicide,
other anxiety, and major depression were used as outcome
variables, we modeled the odds of having the condition
versus the odds of not having the condition.
To extend interpretation of selected regression findings,
bivariate analyses were performed among the deployed to
further examine the relationship between combat intensity
score and health outcomes among those who reported anti-
malarial use and those who did not.
Survey responses were weighted to account for non-
response. The resultant weights were modified using a post-
stratification approach to reduce bias resulting from the
misclassification of deployment in the sampling frame.54,55 All
statistics reported, except for counts, were weighted.
RESULTS
Of 20,563 respondents, a total of 1,076 individuals were
excluded from analysis based on responses to antimalarial
medication use duringmilitary service: “don’t know” (N= 150),
failure to endorse any selection (N = 818), endorsement of
four or more antimalarials (N = 91), and self-reporting non-
antimalarial drugs (N = 17). The final analytical sample con-
tained 19,487 individuals.
Table 1 provides descriptive statistics on demographic and
service characteristics by reported antimalarial use. Amajority
(N = 11,100; 61.4%) of veterans reported receiving no anti-
malarial drugs, whereas 23.5% (N = 4,952) reported receiving
thesemedications but did not providemedication information.
Another 3,435 participants (15.1%) reported receiving an an-
timalarial and could identify the medication. Of those en-
dorsing one or more antimalarials, doxycycline (45.2%),
mefloquine (aloneor reportedwith other antimalarials, 23.3%),
and chloroquine (10.4%) were the most frequently reported
(not shown in tables).
Chi-square tests of association for each respondent char-
acteristic by antimalarial drug status were statistically signifi-
cant (P < 0.0001) (Table 1). Use of antimalarial medication was
more frequently reported by males than by females and was
more prevalent among participants aged 35 years and older
when compared with those who did not report receiving an-
timalarial medications. Participants who reported receiving
one ormore specific antimalarial medicationsweremore likely
to report their race as non-Hispanic white (76.2%) when
compared with those who reported no antimalarial use
(70.0%)or anunknown typeof antimalarialmedication (70.5%).
Antimalarial use (i.e., known or unknown type) was more
prevalent among those who served in the Army (56.9%) than
among those who served in the Marine Corps (15.3%), Air
Force (15.1%), or Navy (12.7%) (not reported in tables). Those
who deployed to Iraq or Afghanistan were more likely to report
receiving some form of antimalarial medication (known or un-
known type) than those who were not deployed (76.1% and
23.9%, respectively) (not reported in tables).
Statistics on the prevalence of participants reporting poor
physical andMH (SF-12), endorsement of thoughtsof death or
self-harm or positive screens for PTSD, other anxiety disor-
ders, and major depression are in Table 2. Among deployed
participants, those who received an antimalarial were more
likely than those who did not use an antimalarial to report
higher prevalence of all six health outcomes included in this
study. Specifically, 53.6% of the deployed sample who re-
ported antimalarial use had an SF-12 MH component score
below the U.S. mean (no use = 47.3%), 43.5% had an SF-12
physical health component score below the U.S. mean (no
use = 36.2%), 18.5% screened positive for symptoms of
PTSD (no use = 11.3%), 11.7%endorsed thoughts of death or
self-harm (no use = 8.8%), 12.5% screened positive for
symptoms of other anxiety disorders (no use = 8.2%), and
11.5% screened positive for major depression (no use =
8.1%). There was little variability in the prevalence of out-
comes across specific antimalarial agents, except for prima-
quine which had the lowest reported prevalence across
measured health indices.
When comparing across outcomes (Table 2) among the
deployed, participants who reported receiving chloroquine
reported the highest prevalence of poor physical health and
MH (SF-12); thosewho reported receivingmefloquine and any
other antimalarial (chloroquine, doxycycline, or primaquine)
had the highest prevalence of positive screens for PTSD, other
anxiety disorders, andmajor depression. Theoneexception to
this pattern was for those who reported taking primaquine
alone, which had the lowest reporting for both use (1.4%) and
reported mental and physical health outcomes (SF-12 MH
component score, 41.0%; SF-12 physical health component
score,28.7%;PTSD,6.9%; thoughtsofdeath/self-harm,6.3%;
other anxiety disorders, 1.4%; and major depression, 3.3%).
Relationships between prevalence of adverse outcomes
and antimalarial use status among the nondeployed sample
were not consistent with those observed among the deployed
(Table 2). The nondeployed samplewho endorsed antimalarial
use reported higher prevalence of poor physical health (53.9%
versus 40.3%with no use), screened positive for other anxiety
disorders (9.8% versus 8.6% with no use) and major de-
pression (8.9% versus 8.6%). Further comparison of the
nondeployed reporting no antimalarial use to those reporting
antimalarial use showed nonusers had higher prevalence of
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poor MH (SF-12; 45.2%, no use versus 42.5%, use), positive
PTSD screen (12.7% versus 10.1%), or reported thoughts of
death or self-harm (10.3% versus 10.1%). The highest prev-
alence of poor SF-12 MH Composite Score among the non-
deployed was reported by those who did not endorse
antimalarial use. Participants who were unable to provide in-
formation on the antimalarial used had the highest prevalence
of positive screens for PTSD compared with other singly used
antimalarials or antimalarial combinations.
Comparisons of study outcomes provide evidence of rela-
tionships between antimalarial use and deployment. When all
those who reported antimalarial use were compared on de-
ployment status, the deployed reported higher prevalence
than the nondeployed for poor MH (SF-12; 53.6% versus
TABLE 1
Sociodemographic and military service characteristics of survey respondents by antimalarial drug status (N = 19,487): National Health Study for a
New Generation of U.S. Veterans
Characteristic*†
Antimalarial drug status‡
Reported receiving drug(s), but none specified
(N = 4,952; 23.5%)
Reported receiving one or more drugs
(N = 3,435; 15.1%)
Reported receiving no drugs
(N = 11,100; 61.4%)
−−−−n§ (%k)−−−−
Gender‡
Males 4,233 (90.6) 2,837 (89.5) 8,288 (79.9)
Females 719 (9.4) 598 (10.5) 2,812 (20.1)
Age group{
24–34 1,719 (46.0) 1,215 (46.8) 5,541 (64.1)
35–44 1,247 (23.4) 1,000 (26.7) 2,489 (18.2)
45–54 1,461 (23.8) 928 (21.2) 2,280 (14.1)
³ 55 525 (6.8) 292 (5.3) 790 (3.6)
Education‡
High school/GED 787 (18.3) 350 (12.6) 1,744 (19.4)
Some college/AA** 2,443 (53.2) 1,529 (50.6) 5,585 (54.3)
College or more 1,705 (28.5) 1,550 (36.8) 3,744 (26.3)
Race/ethnicity‡#
Non-Hispanic white 3,438 (70.5) 2,596 (76.2) 7,730 (70.0)
Non-Hispanic black 638 (12.2) 336 (9.3) 1,476 (12.7)
Hispanic 486 (9.8) 228 (6.8) 973 (9.1)
Asian 90 (1.9) 63 (1.9) 223 (2.0)
American Indian or Alaska native 40 (0.8) 24 (0.8) 73 (0.8)
Native Hawaiian or Pacific Islander 38 (0.8) 16 (0.5) 70 (0.6)
Other 186 (4.0) 151 (4.7) 501 (4.9)
Current household income‡
< $35,000 1,072 (26.6) 599 (22.2) 3,119 (35.3)
$35,000–49,999 834 (17.9) 515 (16.9) 1,936 (18.4)
$50,000–74,999 1,152 (23.0) 810 (24.5) 2,449 (20.8)
$75,000–99,999 746 (13.9) 549 (14.1) 1,519 (11.7)
$100,000–149,999 764 (13.3) 600 (14.9) 1,346 (9.8)
³ $150,000 318 (5.3) 330 (7.3) 588 (4.0)
Currently used for wages‡ (% yes) 3,141 (62.2) 1,999 (56.8) 6,604 (58.1)
Marital status‡
Married 3,525 (68.6) 2,426 (68.9) 7,130 (60.7)
Separated/divorced 694 (13.6) 504 (13.9) 1,640 (14.2)
Widowed 21 (0.3) 7 (0.2) 32 (0.2)
Never married/single 698 (17.4) 489 (16.9) 2,261 (24.9)
Service component{
Active duty 2,035 (55.3) 1,223 (50.0) 4,184 (53.7)
Reserve 1,586 (22.1) 1,289 (25.1) 3,875 (26.4)
National guard 1,331 (22.6) 923 (24.8) 3,041 (20.0)
Branch of service{
Army 2,915 (55.3) 2,117 (59.3) 5,540 (45.0)
Air Force 823 (14.9) 605 (15.4) 2,702 (22.8)
Marine Corps 579 (15.5) 385 (15.0) 886 (10.7)
Navy 635 (14.4) 328 (10.2) 1,972 (21.5)
Deployment to OEF/OIF‡ (% yes) 3,706 (71.6) 2,944 (83.3) 5,806 (42.8)
Combat exposure intensity††
0 1,072 (23.4) 576 (16.9) 4,316 (56.2)
1 977 (21.3) 709 (20.6) 1,811 (21.3)
2 1,202 (27.1) 1,001 (29.6) 1,193 (13.7)
3 1,062 (28.2) 899 (33.0) 677 (8.9)
OEF = Operation Enduring Freedom (Afghanistan); OIF = Operation Iraqi Freedom (Iraq).
* Sum of counts may not always equal total because of missing values.
†Association between each of the sociodemographic and antimalarial drug status is statistically significant (P < 0.0001) based on the χ2 test statistic.
‡Self-reported.
§ Sample size (unweighted).
kPercent (weighted).
{Obtained from sampling frame.
# “Other” race/ethnicity represents those who reported themselves as some combination of race and/or ethnicity or undefined.
** Associate of Arts Degree.
††Combat exposure intensity is the sumof a positive response on 3 questionnaire items (ever felt in great danger of being killed; ever seen anyonewounded, killed or dead; ever engaged in direct
combat where you discharged your weapon). Scores range from 0 (not exposed) to 3 (most exposed).
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42.5%), thoughts of death or self-harm (11.7%versus 10.1%),
positive screens for PTSD (18.5% versus 10.1%), other anx-
iety disorders (12.5% versus 9.8%), and major depression
(11.5% versus 8.9%). Relationships between outcome prev-
alence and deployment were less clear for those reporting no
antimalarial use.
Table 3 contains the AORs obtained from the logistic re-
gression models that had no significant first-order interaction
terms, whereas Table 4 contains the AORs based on models
that did. When controlling for demographic and military ser-
vice characteristics alone (model 1, “demographics”), the
odds are elevated for finding a negative health outcome
among those taking any antimalarial medications compared
with the odds for those not taking any antimalarial medica-
tions. Statistically significant elevated odds ratios (ORs) were
found for poor MH (AOR = 1.39, 95% CI: 1.29–1.49), poor
physical health (AOR = 1.23, 95% CI: 1.14–1.32), positive
screen for PTSD (AOR= 1.83, 95%CI: 1.64–2.04), thoughts of
death or self-harm (AOR = 1.31, 95% CI: 1.16–1.47), or posi-
tive screens for other anxiety disorders (AOR = 1.56, 95% CI:
1.38–1.76) and major depression (AOR = 1.45, 95% CI:
1.28–1.65). The addition of deployment as an independent
variable had little effect on estimates. However, the addition of
combat exposure resulted in the loss of statistical significance
for all observed relationships.
Chloroquine showed significant elevated ORs for poor
overall MH (SF-12) in models 1 and 2 (demographic and de-
ployment, respectively: AOR = 1.33, 95% CI: 1.05–1.70;
AOR = 1.30, 95% CI: 1.03–1.66) for users versus nonusers.
These relationships were no longer significant when combat
exposure was added in model 3 (AOR = 1.15, 95% CI:
0.88–1.50).
Significant elevated associations between doxycycline use
and poorMHoutcomewere shown in the demographicmodel
(AOR= 1.21, 95%CI: 1.07–1.37) andwith a positive screen for
PTSD in the demographic (AOR = 1.38, 95% CI: 1.15–1.65)
and deployment models (AOR = 1.22, 95% CI: 1.02–1.47). In
model 3, the AORs for poor overall MH and PTSD weakened
and lost statistical significance (AOR = 0.96, 95% CI:
0.83–1.09 and AOR = 0.96, 95% CI: 0.79–1.15, respectively).
No significant associations were found for mefloquine use
for the MH and physical health outcomes, a finding that con-
tinued across the three models. Adjusted odds ratios ranged
for model 1 from 0.86 (95%CI: 0.54–1.36—major depression)
to 1.36 (95% CI: 0.92–2.01—thoughts of death/self-harm),
whereas for model 3, ORs dropped with no change in signifi-
cance. Reported mefloquine and any other antimalarial use
resulted in significant, elevated associations with a positive
screen for PTSD and other anxiety disorders in the de-
mographic (PTSD: AOR = 1.63, 95% CI: 1.20–2.20; other
anxiety: AOR = 1.63, 95% CI: 1.17–2.27) and deployment
models (PTSD: AOR = 1.45, 95%CI: 1.07–1.97; other anxiety:
AOR = 1.53, 95% CI: 1.10–2.14), whereas adjustment for
combat exposure inmodel 3 resulted in further decreases and
nonsignificance in the AORs (PTSD: AOR = 1.09, 95% CI:
0.79–1.50 (Table 3); other anxiety, among deployed: AOR =
1.26, 95% CI: 0.88–1.81) (Table 4).
Reports of any other antimalarial or antimalarials showed
significant elevated associations with poor physical health
(AOR = 1.23, 95% CI: 1.02–1.49), positive screens for PTSD
(AOR = 1.63, 95% CI: 1.24–2.13), thoughts of death or self-
harm (AOR = 1.42, 95%CI: 1.03–1.96), or positive screens for
other anxiety disorders (AOR = 1.53, 95% CI: 1.12–2.10) and
major depression (AOR = 1.63, 95% CI: 1.19–2.22) in de-
mographic models with similar levels in the deployment
models but generally failed to retain statistical significance
with theadditionof combat exposure inmodel 3 (poor physical
health: AOR = 1.07, 95% CI: 0.87–1.31; PTSD: AOR = 1.14,
TABLE 2
OEF/OIF deployment status and antimalarial drug use (N = 19,487) for selected health outcomes: National Health Study for a New Generation of
U.S. Veterans
OEF/OIF deployment status, antimalarial
drugs received during military service*
All (N = 19,487)
Selected health outcomes*
SF-12 mental health
score (below U.S. mean)
SF-12 physical health
score (below U.S. mean) PTSD
Thoughts of
death/self-harm Other anxiety Major depression
n (%) (%) Mean (SEM)† (%) Mean (SEM)† (%) (%) (%) (%)
Deployed 12,456 (55.7) 50.7 46.7 (0.13) 40.0 49.5 (0.11) 15.1 10.3 10.5 9.9
Antimalarial drug use 6,650 (52.8) 53.6 45.8 (0.18) 43.5 48.8 (0.15) 18.5 11.7 12.5 11.5
Mefloquine 307 (4.4) 51.5 45.6 (0.90) 38.1 51.0 (0.58) 14.2 14.0 10.8 9.3
Chloroquine 274 (3.5) 57.7 46.1 (0.73) 51.8 46.4 (0.79) 18.9 12.8 10.4 11.4
Doxycycline 1,315 (20.5) 53.3 46.1 (0.39) 39.3 49.8 (0.30) 17.9 10.9 11.2 9.8
Primaquine 98 (1.4) 41.0 49.0 (1.15) 28.7 51.0 (0.99) 6.9 6.3 1.4 3.3
Mefloquine + “X”‡ 425 (6.0) 53.0 45.0 (0.80) 44.1 48.4 (0.65) 20.0 10.7 15.3 12.5
Other antimalarials 525 (7.0) 47.2 47.6 (0.61) 44.6 48.3 (0.55) 17.8 10.9 12.1 12.0
Type not specified 3,706 (57.2) 54.8 45.5 (0.24) 45.1 48.4 (0.20) 19.3 12.1 13.3 12.4
No use 5,806 (47.2) 47.3 47.6 (0.18) 36.2 50.2 (0.15) 11.3 8.8 8.2 8.1
Nondeployed 7,031 (44.3) 44.6 48.3 (0.17) 43.2 48.6 (0.15) 10.6 10.3 8.9 8.6
Antimalarial drug use 1,737 (20.8) 42.5 48.7 (0.35) 53.9 46.1 (0.32) 10.1 10.1 9.8 8.9
Mefloquine 39 (2.2) 33.9 52.2 (2.04) 49.0 48.8 (1.67) 7.5 7.0 5.7 3.3
Chloroquine 110 (5.8) 37.2 50.6 (1.06) 47.7 47.8 (1.23) 7.4 9.2 2.5 4.5
Doxycycline 141 (8.8) 41.4 49.1 (1.07) 40.9 49.3 (1.16) 11.1 10.5 7.1 9.1
Primaquine 35 (1.6) 40.7 50.8 (2.06) 42.8 47.6 (2.39) 3.0 5.9 11.0 3.2
Mefloquine + “X”‡ 52 (2.8) 36.8 49.9 (1.65) 51.2 45.7 (1.57) 9.7 7.5 7.3 4.3
Other antimalarials 114 (6.3) 41.0 48.7 (1.56) 58.6 46.0 (1.14) 13.3 15.0 11.2 11.2
Type not specified 1,246 (72.5) 43.7 48.4 (0.43) 56.1 45.5 (0.38) 13.7 9.9 10.8 9.4
No use 5,294 (79.2) 45.2 48.1 (0.19) 40.3 49.2 (0.17) 12.7 10.3 8.6 8.6
OEF = Operation Enduring Freedom (Afghanistan); OIF = Operation Iraqi Freedom (Iraq); PTSD = post-traumatic stress disorder.
* Self-reported; n (unweighted), % (weighted).
†Standard error of the mean.
‡X = 1 or 2 other antimalarials reported.
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TABLE 3
Results of multivariable regression relationship between each of six health outcomes and antimalarial use while controlling for sociodemographic
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Thoughts of death/

































































0.74 (0.46–1.18) 0.56 (0.35–0.87)‡ 0.48 (0.21–1.10) 0.78 (0.31–1.98) 0.19 (0.06–0.67)‡ 0.46 (0.17–1.21)
Mefloquine + any other antimalarial
Model 1:
demographics









0.92 (0.73–1.15) 1.00 (0.80–1.26) 1.09 (0.79–1.50) 0.91 (0.62–1.33) – –
Any other antimalarial (s)
Model 1:
demographics




1.06 (0.87–1.27) 1.26 (1.04–1.53)‡ 1.51 (1.15–1.98)‡ 1.42 (1.03–1.96)‡ 1.47 (1.07–2.01)‡ 1.57 (1.15–2.16)‡
(continued)
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95% CI: 0.86–1.52; other anxiety: AOR = 1.09, 95% CI:
0.78–1.52; major depression: AOR = 1.20, 95%CI: 0.86–1.68)
(Table 3). Thoughts of self-harm and death were an exception
to this pattern for the nondeployed where the odds of self-
harm/death amongusersweremore than three times theodds
among nonusers in model 3 (AOR = 3.14, 95% CI: 1.24–7.94)
(Table 4).
Primaquine usewasweakly, but significantly, associatedwith
poorphysical health (SF-12;AOR=0.63,95%CI:0.42–0.95)and
with a positive screen for other anxiety disorders (AOR = 0.34,
95% CI: 0.12–0.99) (Table 3). Generally, similar reductions to
estimateswithconcomitant losses insignificance forprimaquine
were found for models 2 and 3 after adjusting for deployment
and combat exposure. Exceptions included the estimate for
models 2 and 3 for overall physical health (AOR = 0.64, 95%CI:
0.43–0.97 and AOR = 0.56, 95% CI: 0.35–0.87, respectively);
model 3, other anxiety (AOR=0.19,95%CI: 0.06–0.67) (Table 3);
and the AOR representing the association between primaquine
use and anxiety among the deployed in model 2 (AOR = 0.14,
95% CI: 0.03–0.60) (Table 4).
Associations between health outcome and antimalarial drug
differed significantly when stratified by deployment (Table 4).
The AORs found among the nondeployed were far lower than
those found for veterans deployed to Iraq or Afghanistan for
major depression and its association with antimalarial use
(chloroquine, AOR = 0.13, 95% CI: 0.18–0.88; any antimalarial
use, AOR = 0.62, 95%CI: 0.42–0.90) (model 3), and for anxiety
andchloroquineuse (AOR=0.26, 95%CI: 0.08–0.86) (model 2).
Table 5 provides weighted prevalence estimates of each of
the six outcomes stratified by combat exposure intensity
score (0, 1, 2, or 3) among the deployed. The prevalence of
each outcome increases among antimalarial users with in-
creasing combat intensity score. For the overall MH score, the
prevalenceof a scorebelow theU.S.meanamonguserswith a
combat exposure intensity score of 0 (lowest intensity) was
32.5 that increased to 65.8 for those with a score of 3 (highest
intensity). Prevalence of a score below the U.S. mean ranged
from31.3 to 49.7 for the overall physical health score, from 3.1
to 32.5 for PTSD, from 4.6 to 17.7 for thoughts of death/self-
harm, from2.7 to20.4 for other anxiety, and from3.8 to18.0 for
depression. This positive trend was also observed among
those who did not report antimalarial use.
DISCUSSION
This study surveyed a large population-based sample of
deployed and nondeployed veterans about use of antimalarial
agents and assessed health indices vulnerable to medication
side effects. The findings suggest that there is a burden ofMH
symptoms across the surveyed population, with a greater
burden among the OEF/OIF deployed, regardless of the anti-
malarial medication reported. Although there appeared to be
significant elevated odds of poor mental and physical health
outcomes among thosewho reported antimalarial use relative
to nonusers, once the effect of combat exposurewasadjusted
for, significant relationships generally diminished, implying
that in this large population-based sample, it is the effect of
combat exposure that is driving the MH burden, not the ex-
posure to antimalarial medication.
Thehighest prevalence ofPTSDandother anxiety disorders
was reported by deployed veterans who endorsed use of
mefloquine plus other antimalarials. The highest prevalence of
thoughts of death or self-harm among the deployed was re-
ported by the mefloquine group. Other anecdotal reports and
research indicated that neuropsychiatric side effects of
mefloquine are a risk,3,25–32,40,43–46,56 but more so for those
with prior MH issues,29,33,34 first-time users,31 and








physical health score PTSD
Thoughts of death/





0.92 (0.75–1.13) 1.07 (0.87–1.31) 1.14 (0.86–1.52) – 1.09 (0.78–1.52) 1.20 (0.86–1.68)
CI = confidence interval; PTSD = post-traumatic stress disorder; SF-12 = twelve-item short form.
* Adjusted odds ratios (95% CI); (–) = interaction.
†Model 1 = all independent variables except deployment and combat intensity; model 2 = all independent variables except combat intensity; model 3 = all independent variables (includes
deployment and combat intensity).Wemodeled the oddsof having a score fall below theU.S.mean vs. the oddsof having a score above theU.S.meanwhen theSF-12composite scoreswere used
as outcome variables.WhenPTSD, thoughts of death/self-harm, other anxiety, andmajor depressionwere used as outcome variables, wemodeled the odds of having the condition vs. the odds of
not having the condition. N’s for the logistic regressions ranged from 14,813 to 19,106 depending on which outcomes and sets of independent variables were being examined.
‡ 95% CI does not contain 1.0.
TABLE 4






1.09 (0.93–1.28) 0.62 (0.42–0.90)‡
Chloroquine/anxiety,
model 2†
0.97 (0.60–1.55) 0.26 (0.08–0.86)‡
Chloroquine/major
depression, model 3†
0.95 (0.59–1.54) 0.13 (0.18–0.88)‡
Primaquine/anxiety,
model 2†
0.14 (0.03–0.60)‡ 1.45 (0.35–6.08)
Mefloquine/post-traumatic











1.06 (0.75–1.50) 3.14 (1.24–7.94)‡
CI = confidence interval.
* Adjusted odds ratios (95% CI); (–) = estimates not reported because odds ratios and
associated 95% CIs are smaller than 0.001.
†Model 2 = all independent variables except combat intensity; model 3 = all independent
variables (includes deployment and combat intensity).
‡ 95% CI does not contain 1.0.
§Mefloquine and other antimalarial(s) reported.
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body weight60; still some contend that serious side effects
from mefloquine are rare.2,61–64
Other than the categories of any antimalarials and other
antimalarials in our analysis, only doxycycline andmefloquine
plus any other antimalarial showed the greatest associations
with PTSD and with PTSD and other anxiety disorders, re-
spectively, before the addition of combat exposure to the
models. However, with the inclusion of deployment and
combat exposure to regression models, the ORs associated
with antimalarial use became attenuated for all health out-
comes. Consistent across most health outcomes and all an-
timalarial medications included in the study was the absence
of statistically significant elevated associations when combat
exposure was included in the model. This suggests that
combat and deployment experiences are potent factors as-
sociated with MH outcomes, even in the presence of other
recognized hazards such as medication side effects that may
contribute to morbidity. The positive trend that was observed
when themental and physical health outcomeswere stratified
by combat score intensity supports this finding. These find-
ings do not invalidate the previous anecdotal reports or
studies that indicate that neuropsychiatric side effects of
mefloquine are a risk. Although these findings suggest that
veterans’ MH morbidity is not a result of mefloquine or other
chemoprophylactic agents, further research is warranted to
better understand this relationship.
Theassociations identified formanyof theother antimalarial
agents in this analysis were not followed by primaquine. It
generally had the lowest prevalence of all health indices and
the lowest association with any of the health outcomes. Al-
though primaquine had the second highest prevalence for
other anxiety disorders among the nondeployed, we were
TABLE 5
OEF/OIFcombat exposure intensity andantimalarial druguseamongveteranswhoweredeployed (N=12,456), selectedhealth outcomes:National
Health Study for a New Generation of U.S. Veterans
OEF/OIF CE,*† antimalarial drugs
received during military service*
All (N = 12,456)‡
Selected health outcomes*
SF-12 mental health score
(below U.S. mean)
SF-12 physical health score







(%) (%) (%) (%) (%) (%) (%)
CE = 0 3,736 (28.7) 35.7 30.8 3.6 4.3 3.3 4.0
Antimalarial drug use 1,244 (16.7) 32.5 31.3 3.1 4.6 2.7 3.8
Mefloquine 61 (4.6) 27.3 29.4 6.9 1.6 2.1 3.4
Chloroquine 47 (3.0) 47.3 32.4 3.3 6.3 1.6 6.5
Doxycycline 222 (18.6) 34.8 26.6 3.8 5.8 3.7 3.8
Primaquine 18 (1.3) 39.9 37.3 –§ – – –
Mefloquine + “X”k 48 (3.8) 34.7 26.5 6.7 10.9 9.8 9.8
Other antimalarials 85 (6.3) 16.0 37.1 0.6 3.0 0.6 1.7
Type not specified 763 (62.4) 32.8 32.3 2.7 4.2 2.4 3.6
No use 2,492 (42.3) 37.2 30.6 3.8 4.2 3.6 4.1
CE = 1 2,913 (22.6) 45.6 37.1 8.2 7.0 6.3 6.3
Antimalarial Drug Use 1,438 (20.0) 43.3 38.3 7.2 6.9 5.0 5.9
Mefloquine 73 (4.5) 49.4 36.8 2.7 14.8 9.6 8.4
Chloroquine 59 (3.8) 48.1 49.5 3.3 3.2 4.4 1.8
Doxycycline 271 (19.6) 40.9 34.1 6.3 7.4 4.5 5.2
Primaquine 18 (1.3) 17.0 12.1 6.7 2.2 – –
Mefloquine + “X” 76 (4.6) 36.1 38.5 6.6 3.8 5.6 6.0
Other antimalarials 129 (8.0) 37.1 30.7 1.0 2.2 0.7 3.4
Type not specified 812 (58.3) 45.4 40.7 9.0 7.3 5.6 6.6
No use 1,475 (25.4) 47.7 36.0 9.1 7.2 7.4 6.7
CE = 2 3,128 (24.7) 59.1 45.3 18.7 12.6 13.3 12.1
Antimalarial drug use 2,049 (29.8) 59.0 47.1 19.3 12.2 14.4 12.7
Mefloquine 93 (3.8) 56.5 32.3 10.1 14.4 9.9 8.4
Chloroquine 88 (3.8) 54.0 51.6 17.9 8.0 10.7 9.3
Doxycycline 430 (20.8) 59.1 42.8 16.1 10.2 12.8 10.1
Primaquine 35 (4.5) 51.2 41.5 6.2 2.1 3.7 9.0
Mefloquine + “X” 149 (6.5) 59.4 43.0 12.7 7.8 12.5 10.7
Other antimalarials 158 (6.8) 48.4 47.6 16.6 9.2 12.4 9.8
Type not specified 1,096 (55.8) 60.9 50.3 22.8 14.2 16.4 14.9
No use 1,079 (18.9) 59.3 42.1 17.8 13.3 11.5 11.0
CE = 3 2,513 (24.0) 64.7 48.4 31.9 18.2 20.2 18.3
Antimalarial drug use 1,869 (33.5) 65.8 49.7 32.5 17.7 20.4 18.0
Mefloquine 78 (4.2) 61.6 50.1 29.8 18.9 16.2 14.2
Chloroquine 76 (3.4) 72.6 60.6 37.2 26.1 17.6 21.8
Doxycycline 387 (21.9) 62.8 44.8 31.7 15.1 16.9 14.7
Primaquine 27 (1.2) 45.2 19.8 11.5 17.6 – –
Mefloquine + “X” 152 (7.7) 58.4 50.9 33.5 15.3 22.2 16.9
Other antimalarials 152 (6.9) 67.8 55.5 38.3 21.8 25.0 24.5
Type not specified 997 (54.6) 68.2 50.7 32.4 18.0 21.9 19.1
No use 644 (13.3) 61.6 44.8 30.1 19.5 19.5 19.2
CE = combat exposure; PTSD = post-traumatic stress disorder; OEF = Operation Enduring Freedom (Afghanistan); OIF = Operation Iraqi Freedom (Iraq); SF-12 = twelve-item short form.
* Self-reported.
†Combat exposure intensity, defined from 0 (no combat exposure) to 3 (highest intensity) and was based on responses to three questions from the study questionnaire: 1) “Did you ever feel that
you were in great danger of being killed?” 2) “Did you see anyone wounded, killed, or dead?” 3) “Were you engaged in directed combat where you discharged your weapon?”.
‡Of the 19,487 respondents in analytical sample, 12,456 were deployed. Of these, 166 had missing on combat exposure.
§Cell count is 0.
kX = 1 or 2 other antimalarials reported.
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unable to confirm the existence of other studies that sup-
ported this finding. Primaquine also had the lowest prevalence
for PTSD, thoughts of self-harm, andmajor depression among
both the deployed and nondeployed compared with the other
medications examined. This finding is consistent with other
studies supporting its limited impact on neuropsychiatric
function.23Kolifarhoodet al.65 conducted ameta-analysis and
concluded that primaquine had generally equivalent or lesser
neuropsychiatric effects than other antimalarial medications.
Astudyof 203Australianmilitarypersonnel66 showednosigns
of neuropsychiatric effects, except for headache that was
reported to be mild in severity and transient. A study of leisure
travelers toEthiopia included106peoplewhowereprescribed
primaquine, one participant withdrew because of GI com-
plaints.67 However, in a randomized, placebo-controlled trial,
the risk of headache (relative risk = 0.62, P < 0.05) was sig-
nificantly higher among those treatedwith primaquine than for
those given a placebo.68
The association between reported use of other antimalarial(s)
and thoughts of death/self-harm among the nondeployed is in-
teresting, both inmagnitude and significance (AOR = 3.14, 95%
CI: 1.24–7.94). We did not expect to find this. Although these
individuals did not deploy to OEF/OIF, they may have been
stationed in other places where malaria is endemic (Africa,
Central America, and South America), requiring the use of anti-
malarial medication. Although our survey asked about common
antimalarial medications, the list was not exhaustive. There
are three common antimalarial medications that were not spe-
cifically queried in our survey, including Qualaquin® (quinine)
(Mutual Pharmaceutical Company, Inc., Philadelphia, PA),
Plaquenil® (hydroxychloroquine) (Concordia Pharmaceuticals
Inc.,Oakville,Ontario,Canada), andMalarone® (atovaquoneand
proguanil) (GlaxoSmithKline, Philadelphia, PA), all of which have
psychiatric side effects.46,69 It is possible that nondeployed
servicemembers serving in other malaria-endemic parts of the
world took these antimalarials and experienced psychiatric side
effects, or experienced other events during their time in the mil-
itary that would have resulted in a poor MH outcome.
The study has several strengths including the use of vali-
dated scales measuring health outcomes of concern.49,50,52
This is the first population-based studyofOEF/OIF veterans to
examine the long-term effects of antimalarial use on mental
and physical health outcomes. The stratified sample design
was used to obtain representative estimates of several pop-
ulation subgroups ofmajor interest that included the branches
of the military; the reserve, National Guard and active duty;
and deployed and nondeployed service personnel. Survey
responses were weighted to reduce bias resulting from non-
response and misclassification of deployment status54 and
women were oversampled to maximize their inclusion in the
study.41 The stratified complex survey design served to re-
duce variance (increase precision) of the point estimates
generated for subgroups of this population.
The study relies on self-reported data for type of anti-
malarial medication, which is acknowledged as aweakness.
The number of individuals reporting specific medications
was sufficient to conduct robust analyses, but 23.5% of
individuals reported use of antimalarials without specifying
type and 61.4%comprised individuals who reported no use.
Health indices only measured current symptoms, not
symptoms experienced historically or potentially related to
medications. The absence of data regarding side effects
related to medication use is a shortcoming; however, the
objective of this study was to assess chronic impact on
neuropsychiatric symptoms, not all the side effects of
medication use, most of which are acute in nature.35
Moreover, we have no data on drug compliance, so we are
unable to determine whether outcomes assessed result
from taking medications as prescribed. There is nomeasure
of deployment duration among the deployed group to as-
certain if multiple opportunities to use antimalarials was
associated with reporting multiple drugs and increased
exposure to both combat and traumatic events. We also did
not collect information on antimalarial administration, so we
have no data on whether reports of “combinations” involved
medications being taken separately or at the same time.
Another limitation of this analysis relates to the time period of
thequestionsused toassessexposureandoutcomes.Exposure
to antimalarial medication was queried during military service
and not specific to an OEF/OIF deployment. Therefore, it is not
possible to determine if the exposure to antimalarial medication
occurred before exposure to combat. Post-traumatic stress
disorderwas assessed in the past 4weeks (fromdate the survey
was filled out), as was anxiety. Major depressive disorder and
self-harm were assessed in the past 2 weeks. The physical and
mental component of the SF-12 assesses experiences in the
past 4 weeks. Combat intensity was assessed during any of a
respondent’s deployments, and not specifically to OEF/OIF
deployments (as servicemembers often have multiple deploy-
ments during multiple wars). In addition, although the MH out-
comesaremeasured in thepast 2or 4weeks, it is not possible to
determine when the respondents began experiencing the MH
outcomes and if it was before or after exposure to antimalarial
medication. While these analyses can determine associa-
tion, temporality cannot be established.
These findings do not invalidate the risks associated with
mefloquine use, including the potential for acute or long-term
neuropsychiatric effects in certain individuals, such as those
with a history of psychiatric illness. Health-care providers,
those serving veterans, and those serving the general pop-
ulation need to carefully consider the potential antecedent
factors and precipitating events, including combat exposure,
when seeking to understand and diagnose psychiatric mor-
bidity or neuropsychiatric effects known to be associatedwith
mefloquine use. Careful assessment of deployment history
andmedication administration should accompany the patient
history during clinical evaluation.
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